Phase III Trial of Enzastaurin for NHL Patients Initiated

Fostering The Future of Psychosocial Care With World Psycho-Oncology Day

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Cristiane Decat Bergerot, PhD

April 14th 2025

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Pembrolizumab/Docetaxel Doesn’t Improve OS/rPFS Outcomes in mCRPC

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

Viviana Cortlana, MS4;Kennedy Itodo, BS;Yan Leyfman, MD;Jenna Ghazal, BSc;Vraj JigarKumar Rangrej, MBBS;Adhith Theyver;Chandler H. Park, MD, FACP

Disparities in Treatment/Survival Outcomes Observed in Metastatic PDAC

Artificial intelligence may mitigate overdiagnosis and unnecessary treatments in cancer cancer care by integrating with precision medicine.

Related Content

Roman Fabbricatore

Fostering The Future of Psychosocial Care With World Psycho-Oncology Day

Higher social vulnerability index was independently associated with lower odds of meeting at least one quality criterion in treatment for PDAC.

Cristiane Decat Bergerot, PhD

April 14th 2025

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

April 7th 2025

Pembrolizumab/Docetaxel Doesn’t Improve OS/rPFS Outcomes in mCRPC

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

Viviana Cortlana, MS4;Kennedy Itodo, BS;Yan Leyfman, MD;Jenna Ghazal, BSc;Vraj JigarKumar Rangrej, MBBS;Adhith Theyver;Chandler H. Park, MD, FACP